Skip to main content

Table 1 Estimated Effects of Interventions (based on model of AMRA region) and assumed Compliance data that were inputted into POPMOD model.

From: Prevention, screening and treatment of colorectal cancer: a global and regional generalized cost effectiveness analysis

Intervention Description Decrease
in Incidence
Decrease
in
Case-Fatality Rate
Compliance
FOB1 Annual Fecal Occult Blood Testsa 35.0% 0% 56.8%
FOB2 Biannual Fecal Occult Blood Testsa 21.9% 0% 61.8%
SIG5 Sigmoidoscopy every 5 years[1]a 38.9% 0% 45.0%
COL10 Colonoscopy every 10 yearsa 52.6% 0% 45.0%
FOB1SIG5 Annual FOBT, SIG every 5 yearsa 51.5% 0% 45.0%
FOB50 FOBT at age 50a 2.6% 0% 71.8%
SIG50 Sigmoidoscopy at age 50a 11.8% 0% 55.0%
COL50 Colonoscopy at age 50a 25.9% 0% 55.0%
FOBSIG50 FOBT & SIG at age 50a 13.2% 0% 55.0%
RX Medical Treatment of cancersb 0% 91.9% 100%
FOB1RX Combination of FOB1 & RX 35.0% 17.9%c 56.8%
FOB2RX Combination of FOB2 & RX 21.9% 12.9%c 61.8%
SIG5RX Combination of SIG5 & RX 38.9% 3.4%c 45.0%
COL10RX Combination of COL10 & RX 52.6% 3.9%c 45.0%
FOB1SIG5RX Combination of FOB1SIG5 & RX 51.5% 18.3%c 45.0%
FOB50RX Combination of FOB50 & RX 2.6% 0.5%c 71.8%
SIG50RX Combination of SIG50& RX 11.8% 0.3%c 55.0%
COL50RX Combination of COL50& RX 25.9% 0.4%c 55.0%
FOBSIG50RX Combination of FOBSIG50 & RX 13.2% 0.5%c 55.0%
FVCAMP Fruit & Vegetables campaign d) 0% ---
FVCAMPRX Combination of FVCAMP & RX d) 0%c ---
DRE1 Digital Rectal Exam annuallya 17.6% 0% 50%
DRE1RX Combination of DRE1 & RX 17.6% 1.8%c 50%
  1. Notes:
  2. Subscripts 1,2,5,10 (eg: SIG5] in the intervention column denote the frequency of screening in years.
  3. Subscript 50, denotes a one off intervention at age 50.
  4. RX denotes the availabily of treatments for cancers in addition to the intervention program.
  5. Efficacy varied slightly between regions due to demographic differences.
  6. Efficacy considered on an age-sex specific basis.
  7. a) Denotes colonoscopy performed on all positive tests, with subsequent removal of lesions or polyps if discovered.
  8. b) Including surgical, radiotherapy and chemotherapy.
  9. c) In excess of decrease in CFR caused by treatment.
  10. d) Varies by region